news-med.jpg

Evotec and Carna Biosciences collaborate on INDiGO platform

Evotec leverages INDiGO platform to accelerate the development of Carna's programme CB-1763 through to IND filing IND-filing envisaged for first half of 2019 INDiGO, a key value-driving component of Evotec's EVT Execute business segment, accelerates early drug candidates into the clinic by reducing ...

Topics: Corporate, INDiGO, Carna Biosciences, Blood cancer Read More

Most Read

Posts by Topic